Targeted therapy for advanced non-small cell lung cancer with driver gene-positive
10.3760/cma.j.cn371439-20200911-00047
- VernacularTitle:驱动基因阳性晚期非小细胞肺癌靶向治疗
- Author:
Chenguang YANG
1
;
Zhiqiao XU
Author Information
1. 新乡医学院研究生院 453003
- Keywords:
Carcinoma, non-small cell lung;
Molecular targeted therapy;
Driver gene
- From:
Journal of International Oncology
2021;48(4):235-240
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, molecular targeted therapy has effectively improved the prognosis of advanced non-small cell lung cancer (NSCLC) patients with driver gene-positive, of which the efficacy is particularly significant for NSCLC patients with human epidermal growth factor receptor gene mutation, echinoderm microtubule-associated protein-4-anaplastic lymphoma kinase fusion gene, ROS1 gene rearrangement, etc. The selection of targeted therapy drugs is particularly important for advanced NSCLC patients with positive driver genes.
